Extensions

To provide a complete and accurate analysis of US patent 12216339's term adjustments, extensions, related applications, and expiration date, direct access to the USPTO's Patent Center or Public PAIR system is essential. This allows for the retrieval of specific data such as the Issue Notification, which details any Patent Term Adjustment (PTA) calculation, and the application's prosecution history for identifying continuations, divisionals, and any terminal disclaimers.

However, based on the provided patent text and general knowledge of patent law, here's what can be stated:

Patent Term Adjustments (PTA)
Patent Term Adjustment (PTA) is granted to compensate applicants for delays caused by the USPTO during the prosecution of a utility or plant patent application. This adjustment is added to the standard 20-year patent term. The USPTO automatically calculates the PTA and includes it in the Issue Notification Letter. The calculation considers various delays, including the USPTO's failure to:

• Issue a first office action within 14 months of filing.
• Respond to applicant replies within four months.
• Issue a patent within 36 months from the filing date, or within four months after payment of an issue fee.
• Any time consumed by continued examination requested by the applicant, or by certain proceedings, is generally excluded from PTA calculations.

Without direct access to the Issue Notification for US12216339, the specific PTA granted cannot be determined.

Patent Term Extensions (PTE)
Patent Term Extensions (PTE) are distinct from PTA and are awarded to compensate for delays incurred in obtaining regulatory approval for a patented product, typically for human drugs, food or color additives, medical devices, animal drugs, and veterinary biological products. The maximum PTE is generally five years, and it cannot extend the patent term over 14 years from the date of receipt of marketing approval.

Given that US12216339 relates to "Eyewear systems, apparatus, and methods for providing assistance to a user" and is not described as covering a product requiring regulatory approval like a drug or medical device, it is highly unlikely to have received a Patent Term Extension under 35 U.S.C. § 156.

Continuation Applications, Divisional Applications, and Related Family Members
The patent text states that US12216339 is a continuation of Non-provisional application Ser. No. 16/736,593, filed on Jan. 7, 2020.

• US 16/736,593 (filed Jan. 7, 2020) is titled "EYEWEAR SYSTEMS, APPARATUS, AND METHODS FOR PROVIDING ASSISTANCE TO A USER." This application, in turn, is a continuation-in-part of Non-provisional application Ser. No. 16/711,340, filed on Dec. 11, 2019.
• US 16/711,340 (filed Dec. 11, 2019) is titled "MODULARIZED EYEWEAR SYSTEMS, APPARATUS, AND METHODS." This application claims the benefit of priority from two U.S. Provisional Patent Applications:
  • U.S. Provisional Patent Application Ser. No. 62/778,709, filed on Dec. 12, 2018, and titled "MODULARIZED EYEWEAR SYSTEM WITH INTERCHANGEABLE FRAME AND TEMPLES WITH EMBEDDED ELECTRONICS FOR MOBILE AUDIO-VISUAL AUGMENTED AND ASSISTED REALITY."
  • U.S. Provisional Patent Application Ser. No. 62/873,889, filed on Jul. 13, 2019, and titled "WEARABLE DEVICES APPARATUSES, SYSTEMS, AND METHODS."
• Additionally, US 16/736,593 claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 62/789,818, filed on Jan. 8, 2019, and entitled "MODULARIZED EYEWEAR SYSTEM WITH INTERCHANGEABLE FRAME AND TEMPLES WITH EMBEDDED ELECTRONICS FOR AUGMENTED REALITY AND ACTIVITY MONITORING."

Therefore, the earliest priority date for US12216339 is December 12, 2018, from U.S. Provisional Patent Application Ser. No. 62/778,709.

No divisional applications are explicitly mentioned as being filed from US12216339 or its direct parent applications within the provided text. A divisional application typically results from a restriction requirement during prosecution.

Projected Expiration Date
For U.S. patents issued from applications filed on or after June 8, 1995, the patent term generally ends 20 years from the earliest effective U.S. filing date (or that of a prior U.S. non-provisional or PCT application from which it claims priority). This term can be adjusted by PTA.

Given the earliest priority date of December 12, 2018, the base expiration date (before any PTA) would be December 12, 2038.

The Google Patents page for US12216339B2 lists an "Anticipated expiration" date of 2039-12-11. This suggests that approximately one year of Patent Term Adjustment was granted (December 12, 2038, plus nearly one year, equals December 11, 2039). The final and official PTA, however, would be stated in the patent's Issue Notification.

A terminal disclaimer can also shorten a patent's life if it repeats claims of a patent that expires sooner. There is no information in the provided text to suggest that a terminal disclaimer was filed for US12216339.

Therefore, the projected expiration date, including the anticipated PTA, is December 11, 2039.